Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.67 -0.03 (-0.00%) Dow
39,056.39 +172.13 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
62,079.08 -1,065.03 (-1.69%) CMC Crypto 200
1,322.44 +27.77 (+2.14%)
Dyadic International, Inc. (DYAI)
| Previous close | 1.4100 |
| Open | 1.4423 |
| Bid | 1.0600 x 200 |
| Ask | 1.8900 x 200 |
| Day's range | 1.4423 - 1.5000 |
| 52-week range | 1.1900 - 2.4000 |
| Volume | |
| Avg. volume | 22,588 |
| Market cap | 42.832M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Dyadic to Attend Industry and Investor Events in May
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry and investor ev
- GlobeNewswire
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on
- GlobeNewswire
Dyadic Reports 2023 Full Year Results and Recent Company Progress
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing topline clinical safety d
